VC-backed Clementia wraps up Nasdaq IPO, raises $174 mln
Montréal clinical-stage biopharmaceutical company Clementia Pharmaceuticals Inc has wrapped up its initial public offering on the Nasdaq Global Market. The company raised an additional $22 million (US$17.9 million) in proceeds from the offering's greenshoe option, bringing total proceeds to about $174 million (US$137.9 million). Its shares began trading on Nasdaq earlier this month under the symbol "CMTA". Founded in 2010, Clementia has been backed by BDC Capital, Fonds de solidarité FTQ, Janus Henderson Investors, OrbiMed Advisors and New Enterprise Associates.
22 August 2017•2 mins read
